While regulation of stability seems to be the main pathway controlling GRK2 dosage, changes in mRNA transcription have also been reported in several pathological conditions, including hypertension, cardiac hypertrophy, and heart failure (Cannavo and Koch, 2018; Mayor et al., 2018). The gene discussed is GRK2; the disease is cardiac hypertrophy.